Sirtuins as therapeutic targets for improving delayed wound healing in diabetes

J Drug Target. 2022 Nov;30(9):911-926. doi: 10.1080/1061186X.2022.2085729. Epub 2022 Jul 12.

Abstract

Sirtuins are a vast family of histone deacetylases, which are NAD+ dependent enzymes, consisting of seven members, namely SIRT 1, SIRT 6 and SIRT 7 located within the nucleus, SIRT 2 in the cytoplasm and SIRT 3, SIRT 4 and SIRT 5 in the mitochondria. They have vital roles in regulating various biological functions such as age-related metabolic disorders, inflammation, stress response, cardiovascular and neuronal functions. Delayed wound healing is one of the complication of diabetes, which can lead to lower limb amputation if not treated timely. SIRT 1, 3 and 6 are potent targets for diabetic wound healing. SIRT 1 deficiency reduces recruitment of fibroblasts, macrophages, mast cells, neutrophils to wound site and delays wound healing; negatively expressing MMP-9. The SIRT 1 mediated signalling pathway in diabetic wound healing is the SIRT 1-FOXO-c-Myc pathway. On the contrary, SIRT 3 deficiency impairs proliferation and migration of fibroblasts and SIRT 6 deficiency impairs wound closure rate and interrupts the vascular remodelling. This review focuses on the role of sirtuins in improving delayed wound healing in diabetes and its natural modulators with their specific functions towards healing diabetic wounds.

Keywords: Sirtuins; diabetic wound healing; fibroblasts; keratinocytes; macrophages.

Publication types

  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus, Experimental*
  • Humans
  • Matrix Metalloproteinase 9
  • NAD
  • Sirtuins* / metabolism
  • Wound Healing

Substances

  • NAD
  • Matrix Metalloproteinase 9
  • Sirtuins